Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
- Conditions
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Keck School of Medicine at U.S.C., Los Angeles, California, United States
🇺🇸U California Medical Center, San Francisco, California, United States
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Fairview University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00006056
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
- Conditions
- Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable ImmunodeficiencyGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeChronic Granulomatous Disease
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00006054
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 300
- Registration Number
- NCT00004686
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 315
- Registration Number
- NCT00004784
Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 90
- Registration Number
- NCT00004748
Stem Cell Transplantation for Metastatic Solid Tumors
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2021-11-10
- Target Recruit Count
- 42
- Registration Number
- NCT00001880
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Antifolate Effectiveness in Arthritis
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 40
- Registration Number
- NCT00000395
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
Autoimmunity in Inner Ear Disease
- Conditions
- Locations
- 🇺🇸
University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸Johns Hopkins Univ, Baltimore, Maryland, United States
🇺🇸Univ of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.